Alok Shetty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alok Shetty has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Bhausaheb Bagal
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
6 shared publications - Hasmukh Jain
Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
6 shared publications - Manju Sengar
Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
6 shared publications - Thomas Eipe
Tata Memorial Centre, Homi Bhabha National Institute
5 shared publications - Lingaraj Nayak
Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
4 shared publications Jayashree Thorat
3 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 49 (1)
Process Characterization and Determinants of CD3⁺ Cell Yield During Autologous Leukapheresis for CAR-T Cell Manufacturing: A Single-Centre Experience from Western India
- 19 October 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 49 (1)
Open AccessProcess Characterization and Determinants of CD3⁺ Cell Yield During Autologous Leukapheresis for CAR-T Cell Manufacturing: A Single-Centre Experience from Western India
- Open Access
- 19 August 2026
- Published by Elsevier in Blood Global Hematology
Safety and feasibility of outpatient induction with intensive monitoring in AML: pilot study and extension cohort
- 19 August 2026
- Published by Elsevier in Blood Global Hematology
Open AccessSafety and feasibility of outpatient induction with intensive monitoring in AML: pilot study and extension cohort
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500443
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
PURPOSE: The 2022 European LeukemiaNet (ELN22) genetic risk stratification for AML makes critical changes, including removal of FLT3- internal tandem duplications (ITD) allelic ratio and inclusion of mutations in myelodysplasia-related (MR) genes and in-frame bZIP CEBPA mutations. We evaluated the applicability of ELN22 in a uniformly treated younger AML cohort and explored refinements to improve risk prediction. METHODS: We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry. RESULTS: A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3 -ITD, CEBPA , and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3 -ITD comutated NPM 1 dichotomized the ELN22 intermediate-risk group. CONCLUSION: We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1 , and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500443
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
PURPOSE: The 2022 European LeukemiaNet (ELN22) genetic risk stratification for AML makes critical changes, including removal of FLT3- internal tandem duplications (ITD) allelic ratio and inclusion of mutations in myelodysplasia-related (MR) genes and in-frame bZIP CEBPA mutations. We evaluated the applicability of ELN22 in a uniformly treated younger AML cohort and explored refinements to improve risk prediction. METHODS: We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry. RESULTS: A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3 -ITD, CEBPA , and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3 -ITD comutated NPM 1 dichotomized the ELN22 intermediate-risk group. CONCLUSION: We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1 , and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2500262
Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection
PURPOSE: Anticancer therapy increases the risk of hepatitis B virus (HBV) reactivation in patients with occult hepatitis B infection (OHBI), particularly in those who receive rituximab or stem-cell transplantation. However, the exact risk of HBV reactivation in patients with ALL/lymphoblastic lymphoma (LBL) receiving prolonged, intensive myelosuppressive chemotherapy is not known and thus the role of antiviral prophylaxis is not clearly established. PATIENTS AND METHODS: This prospective observational study was conducted at a single tertiary cancer center in India (October 2017 to August 2021). Patients age 15 years and older with ALL/LBL were screened for OHBI and enrolled. Liver function tests and HBV DNA levels were monitored at baseline, during treatment, and throughout follow-up phase. During episodes of hepatitis, extended serology panel was performed. The primary end point was the incidence of HBV reactivation. RESULTS: OHBI was identified in 30.4% (172/566) of patients treated at our center during the study period. In the prospective cohort, 65 patients with ALL/LBL and OHBI, treated on a pediatric-inspired protocol, were enrolled. HBV reactivation occurred in six patients (9.2%; 95% CI, 4.3 to 18.7), none of whom developed HBV-related hepatitis. Seventeen patients experienced at least one episode of grade ≥3 hepatitis, with a median AST of 401 U/L (range, 192-3,490) and ALT of 430 U/L (range, 255-1,950). Hepatitis led to chemotherapy delays in five patients, with a median delay of 15.5 days (range, 7-39). CONCLUSION: Our findings indicate a moderate to high risk of HBV reactivation in ALL/LBL patients with OHBI treated with pediatric-inspired protocols, particularly during maintenance, supporting prophylactic antiviral therapy as standard practice in regions with high or intermediate HBV endemicity.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2500262
Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection
PURPOSE: Anticancer therapy increases the risk of hepatitis B virus (HBV) reactivation in patients with occult hepatitis B infection (OHBI), particularly in those who receive rituximab or stem-cell transplantation. However, the exact risk of HBV reactivation in patients with ALL/lymphoblastic lymphoma (LBL) receiving prolonged, intensive myelosuppressive chemotherapy is not known and thus the role of antiviral prophylaxis is not clearly established. PATIENTS AND METHODS: This prospective observational study was conducted at a single tertiary cancer center in India (October 2017 to August 2021). Patients age 15 years and older with ALL/LBL were screened for OHBI and enrolled. Liver function tests and HBV DNA levels were monitored at baseline, during treatment, and throughout follow-up phase. During episodes of hepatitis, extended serology panel was performed. The primary end point was the incidence of HBV reactivation. RESULTS: OHBI was identified in 30.4% (172/566) of patients treated at our center during the study period. In the prospective cohort, 65 patients with ALL/LBL and OHBI, treated on a pediatric-inspired protocol, were enrolled. HBV reactivation occurred in six patients (9.2%; 95% CI, 4.3 to 18.7), none of whom developed HBV-related hepatitis. Seventeen patients experienced at least one episode of grade ≥3 hepatitis, with a median AST of 401 U/L (range, 192-3,490) and ALT of 430 U/L (range, 255-1,950). Hepatitis led to chemotherapy delays in five patients, with a median delay of 15.5 days (range, 7-39). CONCLUSION: Our findings indicate a moderate to high risk of HBV reactivation in ALL/LBL patients with OHBI treated with pediatric-inspired protocols, particularly during maintenance, supporting prophylactic antiviral therapy as standard practice in regions with high or intermediate HBV endemicity.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400482
Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
PURPOSE: Over the past decade, there have been significant advancements in the treatment of AML. However, similar progress has not been observed in India, with induction mortality rates surpassing those in high-income countries. Our patient population also differs significantly from those in clinical trials, with about 50% ineligible for intensive chemotherapy. Yet, because of limited access to newer therapies and high costs, most of these patients receive intensive therapy. PATIENTS AND METHODS: In this study, we retrospectively classified patients who received intensive induction into fit and unfit groups on the basis of landmark trial criteria. Data were extracted from the Indian Acute Leukemia Research Database, a prospective registry maintained under the Hematology Cancer Consortium. The primary objective was induction mortality. RESULTS: We analyzed 385 patients with AML treated between 2017 and 2019. The median age at diagnosis was 33 years (range, 15-61). Induction mortality was reported at 6.1% in the fit cohort and 20.2% in the unfit cohort (odds ratio, 3.91 [1.97-7.74]; P < .0001). Factors such as increased age, poor performance status, baseline infection, and low albumin were associated with a poor prognosis for early death. After a median follow-up of 19.2 months, the 2-year overall survival in the overall, fit, and unfit cohorts was 62.7%, 67%, and 58.1%, respectively. CONCLUSION: Our findings highlight the baseline characteristics of our patient population and their impact on the outcomes of induction therapy. Unfit patients who received intensive chemotherapy had higher induction mortality and lower overall survival.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400482
Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
PURPOSE: Over the past decade, there have been significant advancements in the treatment of AML. However, similar progress has not been observed in India, with induction mortality rates surpassing those in high-income countries. Our patient population also differs significantly from those in clinical trials, with about 50% ineligible for intensive chemotherapy. Yet, because of limited access to newer therapies and high costs, most of these patients receive intensive therapy. PATIENTS AND METHODS: In this study, we retrospectively classified patients who received intensive induction into fit and unfit groups on the basis of landmark trial criteria. Data were extracted from the Indian Acute Leukemia Research Database, a prospective registry maintained under the Hematology Cancer Consortium. The primary objective was induction mortality. RESULTS: We analyzed 385 patients with AML treated between 2017 and 2019. The median age at diagnosis was 33 years (range, 15-61). Induction mortality was reported at 6.1% in the fit cohort and 20.2% in the unfit cohort (odds ratio, 3.91 [1.97-7.74]; P < .0001). Factors such as increased age, poor performance status, baseline infection, and low albumin were associated with a poor prognosis for early death. After a median follow-up of 19.2 months, the 2-year overall survival in the overall, fit, and unfit cohorts was 62.7%, 67%, and 58.1%, respectively. CONCLUSION: Our findings highlight the baseline characteristics of our patient population and their impact on the outcomes of induction therapy. Unfit patients who received intensive chemotherapy had higher induction mortality and lower overall survival.
- Open Access
- 31 January 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (3) , 583-602
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.
- 31 January 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (3) , 583-602
Open AccessGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.
- Open Access
- 1 February 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300292
Clinical Utility of Stepwise Bronchoalveolar Lavage Fluid Analysis in Diagnosing and Managing Lung Infiltrates in Leukemia/Lymphoma Patients With Febrile Neutropenia
PURPOSE: Febrile neutropenia (FN) is a serious complication in hematologic malignancies, and lung infiltrates (LIs) remain a significant concern. An accurate microbiological diagnosis is crucial but difficult to establish. To address this, we analyzed the utility of a standardized method for performing bronchoalveolar lavage (BAL) along with a two-step strategy for the analysis of BAL fluid. PATIENTS AND METHODS: This prospective observational study was conducted at a tertiary cancer center from November 2018 to June 2020. Patients age 15 years and older with confirmed leukemia or lymphomas undergoing chemotherapy, with presence of FN, and LIs observed on imaging were enrolled. RESULTS: Among the 122 enrolled patients, successful BAL was performed in 83.6% of cases. The study used a two-step analysis of BAL fluid, resulting in a diagnostic yield of 74.5%. Furthermore, antimicrobial therapy was modified in 63.9% of patients on the basis of BAL reports, and this population demonstrated a higher response rate (63% v 45%; P = .063). CONCLUSION: Our study demonstrates that a two-step BAL fluid analysis is safe and clinically beneficial to establish an accurate microbiological diagnosis. Given the crucial impact of diagnostic delays on mortality in hematologic malignancy patients with FN, early BAL studies should be performed to enable prompt and specific diagnosis, allowing for appropriate treatment modifications.
- 1 February 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2300292
Open AccessClinical Utility of Stepwise Bronchoalveolar Lavage Fluid Analysis in Diagnosing and Managing Lung Infiltrates in Leukemia/Lymphoma Patients With Febrile Neutropenia
PURPOSE: Febrile neutropenia (FN) is a serious complication in hematologic malignancies, and lung infiltrates (LIs) remain a significant concern. An accurate microbiological diagnosis is crucial but difficult to establish. To address this, we analyzed the utility of a standardized method for performing bronchoalveolar lavage (BAL) along with a two-step strategy for the analysis of BAL fluid. PATIENTS AND METHODS: This prospective observational study was conducted at a tertiary cancer center from November 2018 to June 2020. Patients age 15 years and older with confirmed leukemia or lymphomas undergoing chemotherapy, with presence of FN, and LIs observed on imaging were enrolled. RESULTS: Among the 122 enrolled patients, successful BAL was performed in 83.6% of cases. The study used a two-step analysis of BAL fluid, resulting in a diagnostic yield of 74.5%. Furthermore, antimicrobial therapy was modified in 63.9% of patients on the basis of BAL reports, and this population demonstrated a higher response rate (63% v 45%; P = .063). CONCLUSION: Our study demonstrates that a two-step BAL fluid analysis is safe and clinically beneficial to establish an accurate microbiological diagnosis. Given the crucial impact of diagnostic delays on mortality in hematologic malignancy patients with FN, early BAL studies should be performed to enable prompt and specific diagnosis, allowing for appropriate treatment modifications.
- 1 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (13) , 2350-2361
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
PURPOSE: There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation. Docetaxel was assessed as a radiosensitizer in this situation. METHODS: This was a randomized phase II/III study. Adult patients (age ≥ 18 years) with LAHNSCC planned for chemoradiation and an Eastern Cooperative Oncology Group performance status of 0-2 and who were cisplatin-ineligible were randomly assigned in 1:1 to either radiation alone or radiation with concurrent docetaxel 15 mg/m2 once weekly for a maximum of seven cycles. The primary end point was 2-year disease-free survival (DFS). RESULTS: The study recruited 356 patients between July 2017 and May 2021. The 2-year DFS was 30.3% (95% CI, 23.6 to 37.4) versus 42% (95% CI, 34.6 to 49.2) in the RT and Docetaxel-RT arms, respectively (hazard ratio, 0.673; 95% CI, 0.521 to 0.868; P value = .002). The corresponding median overall survival (OS) was 15.3 months (95% CI, 13.1 to 22.0) and 25.5 months (95% CI, 17.6 to 32.5), respectively (log-rank P value = .035). The 2-year OS was 41.7% (95% CI, 34.1 to 49.1) versus 50.8% (95% CI, 43.1 to 58.1) in the RT and Docetaxel-RT arms, respectively (hazard ratio, 0.747; 95% CI, 0.569 to 0.980; P value = .035). There was a higher incidence of grade 3 or above mucositis (22.2% v 49.7%; P < .001), odynophagia (33.5% v 52.5%; P < .001), and dysphagia (33% v 49.7%; P = .002) with the addition of docetaxel. CONCLUSION: The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC. [Media: see text]
- 1 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (13) , 2350-2361
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
PURPOSE: There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation. Docetaxel was assessed as a radiosensitizer in this situation. METHODS: This was a randomized phase II/III study. Adult patients (age ≥ 18 years) with LAHNSCC planned for chemoradiation and an Eastern Cooperative Oncology Group performance status of 0-2 and who were cisplatin-ineligible were randomly assigned in 1:1 to either radiation alone or radiation with concurrent docetaxel 15 mg/m2 once weekly for a maximum of seven cycles. The primary end point was 2-year disease-free survival (DFS). RESULTS: The study recruited 356 patients between July 2017 and May 2021. The 2-year DFS was 30.3% (95% CI, 23.6 to 37.4) versus 42% (95% CI, 34.6 to 49.2) in the RT and Docetaxel-RT arms, respectively (hazard ratio, 0.673; 95% CI, 0.521 to 0.868; P value = .002). The corresponding median overall survival (OS) was 15.3 months (95% CI, 13.1 to 22.0) and 25.5 months (95% CI, 17.6 to 32.5), respectively (log-rank P value = .035). The 2-year OS was 41.7% (95% CI, 34.1 to 49.1) versus 50.8% (95% CI, 43.1 to 58.1) in the RT and Docetaxel-RT arms, respectively (hazard ratio, 0.747; 95% CI, 0.569 to 0.980; P value = .035). There was a higher incidence of grade 3 or above mucositis (22.2% v 49.7%; P < .001), odynophagia (33.5% v 52.5%; P < .001), and dysphagia (33% v 49.7%; P = .002) with the addition of docetaxel. CONCLUSION: The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC. [Media: see text]